K M Erny-Albrecht
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
Brändle M, Erny-Albrecht K, Goodall G, Spinas G, Streit P, Valentine W. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International journal of clinical pharmacology and therapeutics 2009; 47:501-15.
01.08.2009Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
01.08.2009International journal of clinical pharmacology and therapeutics 2009; 47:501-15
Brändle Michael, Erny-Albrecht K M, Goodall G, Spinas G A, Streit P, Valentine W J
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting
Brändle M, Goodall G, Erny-Albrecht K, Erdmann E, Valentine W. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2009; 139:173-84.
21.03.2009Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting
21.03.2009Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2009; 139:173-84
Brändle Michael, Goodall G, Erny-Albrecht K M, Erdmann E, Valentine W J